Vaxart Inc (VXRT) Q1 2024 Earnings Report

Vaxart reported a first quarter of 2024 with modest revenue growth and a substantial operating loss driven by research and development and general and administrative expenses. Revenue totaled $2.181 million, aided by BARDA-related activity and noncash royalties from Inavir in Japan, while gross profit matched revenue at $2.181 million, yielding a gross margin of about 49.6%. The company’s cash position stood at roughly $36.7 million in total cash, cash equivalents and investments, with the cash runway extending into late Q4 2024, assuming ongoing BARDA reimbursements and no material new cash receipts in the near term. Management highlighted meaningful progress across the core pipeline: positive Phase I norovirus data in lactating mothers, expected FDA discussions in mid-2024 to refine the regulatory path for a potential Phase IIb dose-confirmation study, and ongoing preparations to initiate a 10,000-subject Phase IIb COVID-19 trial (XBB construct) potentially as early as Q2 2024, contingent on funding and regulatory alignment. The mix of funding momentum (BARDA support) and strong execution on manufacturing readiness underpins the near-term catalyst profile, though the company remains heavily dependent on external funding and regulatory approvals to extend its cash runway and advance its programs toward pivotal trials. Investors should monitor BARDA funding progress, FDA feedback, and the pace of data readouts from norovirus correlates of protection and immunogenicity endpoints for the COVID-19 program, as these will largely determine the trajectory of next-year milestones and potential value creation.